Episode 93

MSToronto 2026: Unifying MS and the Future of Research

A wrap-up of ACTRIMS-ECTRIMS 2026 – the world’s largest multiple sclerosis (MS) treatment and research congress.

MS Australia Deputy CEO Dr Julia Morahan, Head of Research Dr Tennille Luker and Deputy Head of Research Dr Fiona McKay bring you the highlights from MSToronto 2026 – the 10th Joint ACTRIMS (Americas)-ECTRIMS (European) Meeting and the world’s largest multiple sclerosis (MS) treatment and research congress.

Held in Toronto from 21 to 23 October under the theme ‘Unifying Multiple Sclerosis’, the meeting welcomed more than 7000 people in person and online, with over 300 oral presentations and 1800 posters. Tune in for an in-depth look at how global experts are working together to shape the future of MS care and research.

Topics and themes covered

The panel also discuss older people living with MS, MS prevalence in Australia and MS Australia’s upcoming Symposium on MS Medications (25 November 2026), the 2025 MS Research and Advocacy Priorities Survey and the Lived Experience Expert Panel (LEEP).

Links and further information

Episode transcript

Voiceover: 
Welcome to The Raw Nerve, the official podcast of MS Australia, a conversation space for all things multiple sclerosis. Join us for news and views on the latest research, treatments and advocacy efforts, as well as candid and informative interviews with our community, those living with MS, and their families and carers, together with leading clinicians, researchers and advocates.

Dr Julia Morahan:
Hello and welcome to The Raw Nerve. I’m Dr Julia Morahan, Deputy CEO of MS Australia.

Today, we’re bringing you the highlights from MSToronto 2026—the 10th Joint ACTRIMS-ECTRIMS Meeting—held in Toronto, Canada from the 21st to the 23rd of October.

Every three years, the European and Americas Committees for Treatment and Research in MS come together, and this year more than 7000 people attended in person and online. With over 300 oral presentations and 1800 posters, it is the world’s largest gathering on MS and related disorders, and a remarkable window into where research is heading.

The theme this year was ‘Unifying Multiple Sclerosis’.

It reflects a growing understanding that relapsing and progressive MS are not separate diseases but share underlying processes.

It is also a call to connect research more closely with clinical practice, so that progress reaches the people and communities who need it most.

Joining me today to unpack the highlights are my two colleagues who were with me in Toronto: Dr Tennille Luker, Head of Research at MS Australia, and Dr Fiona McKay, Deputy Head of Research at MS Australia.

Today we’ll explore what a new biological view of MS means for people living with disease, the latest treatment results, and the research shedding light on causes and prevention—including the Australian work presented on the world stage.

Tennille and Fiona—welcome to The Raw Nerve.

Dr Fiona McKay:
Thanks so much, Julia.

Dr Tennille Luker:
It’s great to be here, Julia. Thank you.

Dr Julia Morahan:

Tennille, the meeting’s theme was ‘Unifying Multiple Sclerosis’.

Professor Daniel Ontaneda described two processes at play—acute immune attacks on the brain and spinal cord during relapses, and a slower-burning, more confined immune process in progressive disease.

In plain language, what does this new biological understanding mean, and why is it such a shift from the familiar categories of relapsing-remitting, secondary progressive and primary progressive MS?

Dr Tennille Luker:
Thanks, Julia. So, this new understanding has been heavily influenced by looking back over data from large clinical trials of people with relapsing MS.

So, relapse is only part of the picture and clinical trials show that disability can worsen both with relapses but also independently of relapses which is known as ‘progression independent of relapse activity’ or PIRA.

So, these two processes can happen in parallel. So, sudden immune attacks cause the lesions and relapses we already recognise and there’s also a slower, more contained process within the brain and spinal cord which can gradually cause damage and disability.

So, this means that progressive biology can actually start much earlier than previously thought.

So, relapsing and progressive MS increasingly look like overlapping biological processes rather than completely separate forms of MS.

So, someone with relapsing MS may experience, may already have progressive processes occurring, while someone with progressive MS can still have inflammatory activity.

And so that big shift is moving away from those rigid labels of relapsing remitting MS, secondary progressive MS, and primary progressive MS, towards understanding what biology is active in the individual. And the longer-term goal is more precise and personalised treatment.

Dr Julia Morahan:
That’s right.

So, Fiona these large clinical trials have shown that disability can progress independently of relapses and sometimes from very early in the disease course.

So, what does this mean for someone living with MS today and how are our researchers learning to detect these quieter processes in an individual—for example, through new MRIs or blood tests?

Dr Fiona McKay:
Thanks, Julia.

I might even go to your second question first if I can, because we now understand some of the features that are associated with this slower progressive biology.

So, many are not yet at the stage of being clinical tests yet, but we’re learning more about them. But first up, it might sound obvious, but some of the most important indicators for both patient care and in research studies are how the person reports how they’re feeling themselves and their own function.

So, they might just notice a decline in function even though they haven’t had a relapse and that can be indicative to their clinician or can be used in a research study.

Alongside this, of course, there are clinical measurements such as disability scores changing over time in the absence of relapses and that’s another indicator.

But as you mentioned, we’re also learning more about the MRI features that are associated with MS progression that’s independent of these relapses. So, these include changes in brain volume in specific areas and also MS lesions detected on MRI that expand slowly over time.

Many of these aren’t validated for use in the clinic yet, but we’re learning more about how they might be used in future.

And then the last thing you mentioned are markers in the blood that are associated with progression independent of relapses.

One of these is called glial fibrillary acidic protein or GFAP. And this is produced by astrocytes which are the primary support cells of the brain in response to prolonged inflammation or stress. And studies are suggesting that GFAP might be a good marker to help predict or monitor progression independent of relapses.

So back to your first question, what does this mean for people with MS?

And to return to what Tennille said earlier, this second process, this progressive biology isn’t simply a change in terminology.

It really opens up new avenues for how we might treat MS. So, while our current therapies treat acute attacks or relapse biology very effectively, we really need new options for treating this progressive biology.

And one study from Denmark presented at the meeting showed that starting high-efficacy treatment with some of our current therapies and starting that early, cut relapses by about a third, but it didn’t clearly reduce this silent worsening that happens over time.

So, a new class of drugs known as BTK inhibitors is showing promise in this area. And this class targets the resident immune cells in the brain that really help drive this chronic inflammation associated with progressive biology.

And we’ll talk a bit more about some of the new trials with BTK inhibitors later in the show.

Dr Julia Morahan:
Thanks, Fi.

Yeah, I think the new trials of the BTK inhibitors…we had some very exciting results, which we’ll talk about soon.

But moving on now from new ways of defining MS to better ways of diagnosing MS.

At MSToronto, we heard updates on how the new 2024 diagnostic criteria for MS are performing in the real world.

The diagnostic criteria for MS called the McDonald criteria, are updated periodically to reflect new advances and new understanding with the goal of supporting earlier and more accurate diagnosis.

In MS, we always say that time is brain. The sooner we can start people on disease modifying therapy for MS, the better their outcome.

This was reiterated in a study from London presented at the meeting showing that earlier treatment was linked to preserving the volume of structures deep within the brain.

Tennille, can you tell us a little bit about some of the new tests that were included in the 2024 McDonald criteria?

Dr Tennille Luker:
Sure. So, there’s several new features. So, one of them is the optic nerve is now included.

So, the optic nerve connects the eye to the brain and is commonly affected in MS and evidence of MS-related changes in the optic nerve can now help contribute to a diagnosis.

Another thing is new features on MRI scans. So, new MRI features can help doctors determine whether a brain lesion is more likely to be caused by MS rather than something else. One looks for a small vein running through the centre of a lesion. Another looks for a characteristic rim around certain MS lesions.

Another test is kappa free light chains or kFLC. This is a newer test performed on the fluid surrounding the brain and spinal cord and it looks for signs that the immune system is active within the brain and spinal cord. So, this can now be used as an alternative to the older oligoclonal band tests in the diagnostic criteria and the potential advantage is that it’s a lot more objective, quantitative and much more automatable, so a lot more efficient. And this is particularly relevant in Australia because access to the test through Medicare is currently being considered.

So, the overall significance of these new tests is that it gives neurologists more pieces of evidence to work with when assessing someone for MS. It could help people receive an accurate diagnosis earlier, but it’s still important that the criteria has safeguards to reduce the risk of misdiagnosis.

Dr Julia Morahan:
Yeah, so that’s really fantastic and gives us a number of new tools to allow us to hopefully move a diagnosis of MS into the earlier stages of disease.

Fi, what was the news from MSToronto on how these new diagnostic criteria are performing?

Dr Fiona McKay:
Well, it was great news actually.

So, a study from across six European centres showed us that the new criteria really helped with much earlier diagnosis – around four months compared with about 16 months using the previous criteria. And it also identified about 20% more people with MS than the 2017 criteria.

So, of the new measures, it seems like the addition of the optic nerve testing is increasing the MS diagnosis the most, which is great news.

And there were two other studies presented at the conference that found the same trends.

But I guess the tricky thing is that distinguishing MS-related damage to the optic nerve from damage caused by other conditions can be quite challenging.

And so, one of the presentations outlined a new diagnostic framework, which was developed by international experts, that’s going to really support more accurate assessment of optic nerve damage in MS.

Dr Julia Morahan:
Yeah, so interesting.

So, I really loved this theme of MSToronto of ‘Unifying MS’ because it reflected not only how MS is increasingly being recognised as one disease and also brought clinicians and researchers and people living with MS together as one group, but for me, it also symbolises how our MS networks are unifying as a global community.

I have the privilege of serving on several international research committees and the ACTRIMS-ECTRIMS meetings are always excellent opportunities for these groups to meet in person and allow me to have conversations in person with these people that I work with throughout the year.

So, Australians work internationally across a number of these different groups, including the Global Research Strategy Group of various national MS organisations, the International Progressive MS Alliance, which focuses specifically on treatments for progressive disease, the International Organization of MS Nurses, the International MS Genetics Consortium, and the MS International Federation.

We also have a new initiative spearheaded by MS Australia and MS Canada called the Global MS Prevention Initiative. And this initiative is really honing in on the idea that we can get better tools and better results in terms of earlier detection of MS and ultimately prevention of MS. So together, Australia and Canada have committed $7.5 million towards this initiative.

We’re also working closely with the US National MS Society, the NMSS, who have just launched a new funding call towards risk detection and screening tools for MS that is open internationally.

We have other MS organisations from around the world joining us.

I always really appreciate that the global MS community is extremely collaborative, and we often comment how lucky we are to have this pre-established ‘connective tissue’ to scaffold any new work and bring solutions to our community faster.

Alright, so onto the treatment pipeline, the results and the realistic hope.

Fi, BTK inhibitors were a major focus in MSToronto. Why is this exciting, particularly for people living with progressive MS and what still needs to happen before medicines like this could become available to Australians?

Dr Fiona McKay:
So, the BTK inhibitors, as I mentioned before, are an entirely new class of MS treatment that targets activated immune cells involved in both relapsing and progressive disease. And this drug class may therefore offer new treatment options for different forms of MS.

However, some of the BTKs have been linked to raised liver enzymes and drug-induced liver injury. So, liver safety is really an important consideration when we think about some of these results.

Now at the meeting, the Late-Breaking Abstracts session presents the absolutely hot off the press newest results, including those from final stage clinical trials. And we actually heard two of those on BTK inhibitors at this meeting.

So, the first one was a new phase 3 trial that results were presented for, for a new BTK inhibitor called remibrutinib.

And the trials were called REMODEL-1 and REMODEL-2 and they compared remibrutinib with teriflunomide, also known as Aubagio, in relapsing MS.

So, remibrutinib significantly reduced relapse rates by around 30% and MRI disease activity by around 70% compared with the comparator drug.

They also found a marker of nerve damage in the blood was significantly lower.

And excitingly, disability progression was delayed at both three and six months. And over 90% of participants remained progression-free compared with the comparator drug.

The drug was really well tolerated. And interestingly, there were no liver safety issues identified in this trial.

So overall, the results are suggesting that remibrutinib could become an effective oral treatment for relapsing MS with both significant effects on relapses and MRI but also reduced disability progression and possibly a better safety profile than some of the other BTK inhibitors.

And MS Australia’s November WIRE newsletter coming soon will have some more detail for you to look at on this trial.

We also heard about some more results on fenebrutinib, which is another one in this class.

So, we already have the phase 3 trial results, which had shown previously that it wasn’t inferior to other comparator drugs in either disability progression in primary progressive MS or in reducing relapses compared to the comparator in relapsing MS.

But the new results at MSToronto were looking at more detail about some of these MRI features that we were speaking about before that are associated with progressive MS and disability.

So, the researchers had dug further into looking at the MRI features and there are two that are real indicators of progressive sort of slow burning chronic inflammation in the brain, and they’re called slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs).

And this trial found that against the comparator drugs, fenebrutinib was associated with around 20% less of these slowly expanding lesions.

And also, the volume of these lesions was reduced by around 30%.

And then the other type of lesion, the paramagnetic rim lesion, was also found to be reduced in the fenebrutinib-treated participants.

And so, these findings are really suggesting that fenebrutinibmight be acting on these areas of ongoing inflammation linked to progressive disease, both in relapsing MS and also in progressive MS, which is really exciting news.

And then finally, another BTK inhibitor called orelabrutinib has been shown in a phase 2 trial already in relapsing MS to reduce lesions by about 90%. That’s active lesions.

But there are also two phase 3 trials ongoing in non-active secondary progressive disease and also, in primary progressive disease currently. So, we look forward to seeing the results of those.

Dr Julia Morahan:
I think this is so cool, Fi, because we’re now talking about real differences, hopefully, for progressive disease. And I think we’ve been after this for such a long time, so many years. This is such an unmet need.

And it’s just so pleasing now to see some of these BTK inhibitors actually making a difference on the underlying mechanisms that we suspect are driving progressive disease. It’s very cool.

So where are we at with our BTK inhibitors as a group and nationally for Australians with MS?

Dr Fiona McKay:
So, I suppose the first thing to say that is that we’re learning from the trials that there are some differences between the different inhibitors in their precise effects on relapses, disability progression and their safety profile.

But already one of the BTK inhibitors, tolebrutinib, has been approved in Australia by the Therapeutic Goods Administration. It’s not on the PBS yet, but we understand that there are discussions underway, and we anticipate that others will follow.

Dr Julia Morahan:
It’s very exciting times.

So, we also heard some early results presented from small phase 1 trials of a different type of therapy called CAR T-cell therapy, which aims to reset the immune system, including in people with progressive MS.

So, Tennille, what did we learn about CAR-T and how should listeners balance genuine hope with the caution of the early-stage clinical trials?

Dr Tennille Luker:
So just to give everyone a bit of a rundown. So, CAR T-cell therapy is an experimental treatment that modifies immune cells called T cells. And these modified T cells are designed to recognise and attack specific cells in the body.

So, in MS, CAR T-cells are being tested to target B cells, which are involved in the disease.

And unlike antibody treatments, CAR T-cells may be able to enter the brain and spinal cord. So, this means they could potentially act directly on disease processes in the brain and spinal cord and help reset the immune system, like you mentioned, Julia.

So, CAR T-cells can be made using a patient’s own cells or donor cells. The donor-derived treatments are sometimes described as off-the-shelf. And researchers are exploring ways of creating CAR T-cells inside the body by delivering genetic instructions, which could avoid the need for separate cell manufacturing.

However, CAR T-cell therapy has raised serious safety concerns, and one company recently halted its clinical trials.

In terms of the late breaking abstracts that were presented, there was one early phase trial, phase 1 clinical trial result presented from TG-Azercel-101 or Azer-cel.

And this is an off-the-shelf CAR T-cell therapy that was explored in progressive MS. And it’s designed to target B cells, as I mentioned before, including those involved in immune activity in the brain and spinal cord.

The treatment produces a strong reduction in B cells in the blood and also the fluid surrounding the brain and spinal cord. And it’s showing really encouraging early signs.

Most people remain stable or show some improvement.

There were also encouraging changes based on MRI findings. And the early safety results were generally reassuring. And when the B cells returned, there were signs that the immune system may have been reset. So, it’s less reactive. But it is very early days. It’s a phase 1 study. It’s a very early phase clinical trial. There were only 26 participants. There was no comparison group. And it was a short follow-up period.

So, it really is an interesting proof of concept rather than proof that CAR-T-cells…CAR-T works for progressive MS. We do need larger, longer trials to understand whether it really improves disability, how long any benefits last, longer term safety data, and what the best dose is.

And there was also an interesting debate at the conference about this, like whether CAR-T can offer advantages over existing antibody treatments.

And the potential advantages of CAR-T is being able to reset part of the immune system, being able to enter the brain and spinal cord, as I mentioned before, to target that immune activity. But the key concern is the unknown about the safety. And we don’t know whether CAR-T will be actually better than existing treatments.

And so, like I mentioned before, randomised clinical trials are needed to answer that question.

Dr Julia Morahan:
Yes, I think it was the world’s most polite debate, characterised as such on the day because everybody knows, as Tennille has quite rightly said, we need the randomised clinical trials to answer this question, but it was a very interesting discussion about the pros and cons of each of the treatments.

And I just felt so lucky to be able to have a conversation about having multiple treatments to treat people with MS at all, actually still, because I’ve been around for such a long time. So, it’s still so lovely to be able to have some choices.

So, we’ve already mentioned studies highlighting the benefits of starting effective treatment early, while others explored when it may be appropriate to stop or step down treatment, particularly as people age.

Work from Australian researchers and their collaborators investigated the effect of relapses in older age and the effect of stopping disease modifying therapies for older people.

In people aged 55 and over with stable MS, it seemed that stopping treatment did not increase a risk of relapse, which supports the 2025 ECTRIMS guidance.

For some older people, this may be a safe option, but it must be done in consultation with your healthcare team, paying attention to the person’s disease course over the last five years, treatment history and other individual factors.

So, T, how do these findings connect with what matters most to people living with MS and with protecting treatment choice and access here in Australia?

Dr Tennille Luker:
I think it reinforces just how powerful disease-modifying therapies have become. But there is no single right treatment or treatment strategy for everyone, and everything needs to be done in consultation with their healthcare team. So, decisions about starting, switching, stepping down or stopping treatment need to be individualised.

One of Australia’s strengths is access to a broad range of MS treatments through the Pharmaceutical Benefits Scheme.

So, people who are newly diagnosed can access highly effective therapies as first line treatment, which is a massive strength for Australia compared to a lot of other countries.

Our upcoming Symposium on MS Medications on the 25th of November will reflect on what 30 years of access to disease-modifying therapies has meant for people living with MS in Australia.

And this is particularly timely because the Pharmaceutical Benefits Advisory Committee which advises the Australian Government on medicines subsidised through the PBS is currently reviewing access to MS treatments.

And MS Australia has been working closely with the PBAC throughout this process and supports preserving choice and access to a broad range of MS treatments.

So, this will give people with MS and their healthcare teams the ability to choose a treatment that best suits their MS circumstances, preferences and stage of life.

Dr Julia Morahan:
Thank you, Tennille.

We are very excited about our Symposium which will be coming up more towards the end of November and we do have a fantastic new report that we will be releasing.

We have been so lucky in Australia to have access to a wide range of effective therapies for MS and there is absolutely no doubt that that has improved the outcomes for Australians that have been able to access those medications early and it’s a huge role and point of MS Australia to make sure that we work as hard as we can to keep that for Australians living with MS.

So, we’re going to talk a little bit now about causes and prevention and some Australian research at MSToronto.

So, one of Fi’s all-time favourite topics is Epstein-Barr virus or EBV. And this topic took centre stage this year with more than 60 posters and presentations.

So, Fi, what are the researchers learning about how EBV contributes to MS? And how do you think this might lead to new approaches for prediction, prevention or treatment?

Dr Fiona McKay:
Thanks Julia. Yes, and you’re absolutely right it is my absolute favourite hobby horse.

So, it was very exciting to see all the work being done and the momentum that’s just been incredible over the last few years in EBV and MS. And first up I guess we’re learning more about how EBV might cause MS.

So just a couple of examples.

One study of brain tissue found that there was EBV-infected immune cells in over 50 of the MS brains studies, but none of the control brains suggesting that EBV infection might have a role in MS.

But it’s not as simple as a brain infection.

Other studies have found that there are immune cells that can target EBV that are found within the brain in MS. And importantly, these immune cells that recognise EBV can also recognise or cross-react with proteins that make up the brain tissue.

And this is a phenomenon known as molecular mimicry, and it explains that EBV might actually cause the immune system to mistakenly recognise the brain and attack it in MS. And that’s a huge field of ongoing work by many labs around the world at the moment.

The second thing is that several studies have shown that there’s evidence of being able to see EBV activity prior to the onset of MS. And I guess the hope here is that this might help us with early detection and treatment of MS and possibly even being able to discover that people are at risk of MS before the onset of disease.

For example, there was one study in identical twins where only one twin has MS and the researchers showed that antibodies against a particular EBV protein were found up to eight years prior to diagnosis in the twin who later developed MS. So, this is like really early discovery that someone’s at risk or might be going to go on to develop MS.

Another study looked at whether antibodies to EBV in the blood could be used to predict MS in very large cohorts using machine learning. And these antibodies actually did have reasonable predictive power. They’re not going to be enough alone but used with other risk factors such as genetics might help us to be able to identify people at risk and detect MS earlier.

And then finally, researchers are of course thinking about whether we could treat EBV in order to treat MS.

And I suppose the first thing to say about this is that we might actually already be doing this in part as a byproduct of some of the B cell therapies.

So, once a person is infected with EBV, they actually have it for life and it lives inside the B cells of their immune system, mostly as a fairly silent passenger.

But several studies at the conference showed that people who are on B cell therapies already for their MS actually have less active virus in their B cells and less EBV in their blood and less antibodies to EBV in their blood. So, we may actually be targeting this pathway already with some of the treatments that we’re using.

But looking forward, another strategy to treat EBV and MS may be to use antivirals. And a really fascinating study from the EBV-MS Consortium in Europe showed some results using an antiviral called ternofovir alafenamide. That’s already used for HIV and hepatitis, but it’s also known to block EBV in lab studies.

The treatment in MS was safe and the group found that there were some small reductions in EBV in response to the antiviral. These didn’t reach significance, but the group is going on to conduct further trials with the antiviral at some higher doses.

So, this was really exciting early work, and MS Australia is actually partnering on an Australian clinical trial of tenofovir alafenamide that’s underway at the moment, as well as another antiviral against EBV in a trial called FIRMS-EBV. And there’s a link with more information about this in the show notes if you’d like to read more about that trial.

And finally, another approach to treating EBV in MS is of course vaccination. And EBV vaccine development is underway internationally, including a phase 2 vaccine trial currently underway in MS.

And so, we really look forward to the readouts of those trials as they come.

Dr Julia Morahan:
There’s so much happening. Thanks, Fi.

So, Tennille, Australian researchers presented a wide range of work in Toronto, and we tried to race around and see them all, but they were only three of us and it was completely impossible. But we’re proud of absolutely everybody for flying the Australian flag at the conference.

For you, Tennille, which of the Australian findings stood out and how do you feel that MS Australia’s supported research contributes to the global effort?

Dr Tennille Luker: 

I was going to say exactly the same thing, Julia, we spent so much time trying to find posters and talks from Australians, and there were too many and we couldn’t split ourselves in half. And we tried people, we really tried!

So, there really was a broad Australian research presence. We saw research on MS prevalence and economic impact, ageing and recovery from relapses, pregnancy in MS, employment and income, MS nursing workforce, and many, many more.

One of the ones that stood out for me was Professor Vilija Jokubaitis from Monash University. And she’s been looking at why MS affects more women than men. And some of the possible roles could be genetics, hormones, different immune responses to viruses, amongst other things. She also has been looking at pregnancy in MS and provided a reassuring overall message that pregnancy does not appear to worsen long-term MS outcomes.

And also…she also raised (their) gender-based violence (work) in MS, which highlights the importance of sensitive conversations in healthcare and recognising that some effects of trauma may overlap with MS symptoms.

Another highlight was Dr Samuel Klistorner from the University of Sydney. So, he presented interesting follow-up work from the visionary trial, which tested an experiment treatment using tiny gold particles in people with relapsing MS.

And these are designed to help nerve cells use energy more efficiently, potentially protecting them from damage. And new MRI analysis suggested that the treatment could slow the expansion of those chronic MS lesions we’ve been talking about, which are associated with disability progression.

But the study was very small and once again, we need larger trials.

But these examples showed the breadth and the strength of Australian MS research.

And MS Australia supports this through research grants and national research platforms. And Australian researchers also work as part of major international collaborations, which Julia talked about earlier as well. And that really allows Australian research to contribute to global progress while bringing international expertise and collaboration back to Australia.

Dr Julia Morahan:
Great examples Tennille.

So, many of our listeners follow the progress of MS research closely. Thank you. And want to know about the status of current projects and what’s coming next.

So, Fi, we heard a lot in Toronto. We’ve covered a little bit today. How do you think what we heard could shape MS Australia’s research investment, including our new grants, our national research platforms or opportunities for people living with MS to take part in the research?

Dr Fiona McKay:
Yeah, I think in this day and age, the MS research community is already global, and researchers can access the latest on various platforms and research areas at their fingertips at any time.

But I think the difference that meetings like MS Toronto make is really that dedicated time to come together for focused discussion, sharing the latest data across diverse topics and really seeding new ideas in people that may normally work in a niche and then they hear something else from another part of MS research that might really inspire or teach them something new to take to their research.

You know, it’s 7000 researchers in one place and they have this unified goal of better outcomes for people with MS.

And I really think that, you know, this environment helps everyone with developments across the field and guiding our research investments to be really as informed and as cutting edge as possible.

And you mentioned also opportunities for people living with MS to take part in research.

The Patient Community Day at MSToronto was an excellent opportunity for this, for people living with MS to discuss their priorities for research and really ask questions of the researchers about how the new research will impact daily life with MS for them and their MS treatment.

And you can find the links to the video recordings of this event in the links below our show notes.

But for us at MS Australia, I think this really highlights a critical plank of our research philosophy. And that is that people living with MS must be involved at every stage of the research process from the ideas generation right through to the implementation and the assessment of the research.

And our LEEP or Lived Experience Expert Panel are at the heart of this work that we do. And we really encourage researchers to contact us to find out how to also involve people with MS in their work.

Dr Julia Morahan:
Thanks, Fi.

I think the conference theme of ‘Unifying MS’ sits at the heart of what we do at MS Australia.

As the national MS organisation, we fund, coordinate and advocate for research to better treat, prevent and ultimately cure MS.

We’ve just finished the long slog of grant assessments that we do every year and we will have our 2027 investigator-led grants launched at the start of next year. It’s very exciting.

We also have a number of national collaborative platforms and international collaborative platforms that we’ve touched on today.

But importantly, our research, our research projects, our research platforms and our research strategy is guided by our MS community.

So, periodically we do what we call the Research and Advocacy Priorities Survey, and our most recent one was launched in 2025 and more than 2000 people took part. And really interestingly our community’s top priorities were (firstly) ‘Finding a cure through repair and regeneration’ which makes perfect sense and has always been the top priority of these surveys that we’ve done. But interestingly, second was ‘Preventing MS’ and ‘Improving diagnosis’ has risen in importance.

So, I think that has really guided us in the decisions that we’ve made about our fundings, particularly in our collaborative platform space.

And with a record 37,756 Australians now living with MS, I think that guidance has never mattered more.

So, Tennille, as MS Australia’s Head of Research, can you tell us how MS Australia supports research in Australia and beyond?

Dr Tennille Luker:
Sure. So, we have two main approaches to supporting research.

The first is our investigator-led grants. And these are research grants that researchers can apply for. They undergo an independent peer review process. And thanks to the help of our Research Management Council, they provide recommendations on what should be funded. In this year so far, we’ve actually funded over $2.8 million across 19 projects.

And there’s a broad range of projects that we’re funding from causes and prevention, myelin repair, lifestyle, environmental risk factors, and real-world outcomes, amongst others. And as Julia said, we just finished a massively long slog with this year’s grant rounds, which will be announced February next year, hopefully.

The second way in which we support research is through our national research platforms. And these tackle bigger research questions that need researchers and organisations working together. And by doing this, it helps reduce duplication and accelerate research.

So, for example, we have the Australian MS Clinical Trials Platform, and this supports trials of new approaches for MS progression, fatigue, and nerve protection. Other major platforms include MS Australia’s Brain Bank, which contains tissues, brain tissue for people living with MS who have kindly donated their brains that researchers can use. The vitamin D prevention trial, which we funded, that is now a data resource for researchers to use. The Australian MS Longitudinal Study, which is a survey-based study on patient-reported outcomes. And EBV and MS Research Platform, which Fi spoke about just before.

But Australian research doesn’t happen in isolation.

MS Australia and Australian researchers work with international partners including the International Progressive MS Alliance and the International MS Genetics Consortium amongst others as has been mentioned throughout this podcast. And it really…this really helps Australian research contribute to global progress and benefit from international expertise and collaboration. And I must say, I feel like we punch above our weight when it comes to MS research here.

Dr Julia Morahan:
I agree with you.

Okay, guys. Of everything you saw and heard in Toronto, what was the one finding or moment that gave you the most hope? What a great question. And what would you most like people living with MS to take away from this year’s meeting? Tennille, why don’t you go first?

Dr Tennille Luker:
Sure. It’s really hard to pick one. I mean, the pace of innovation and treatment

development you know… progress is happening across multiple fronts, not just one.

You know, for MOGAD, which is an MS-like disease, we saw the results of the TOMATO trial, which I absolutely love the name of, I think everyone else did too, which is a trial on tocilizumab to treat MOGAD and this would be an effective new treatment for that disease…which ‘likes’ treatments.

We saw BTK inhibitors, which show an encouraging new direction for progressive MS. And this is particularly important given the unmet need, which Julia has mentioned earlier. We’ve seen proof of concept and moving towards treatment development for remyelination inflammation, CAR T-cell therapies, which is a new approach.

But the big takeaway is the breadth and the pace of research. It really gives us hope. And I’m particularly encouraged by the focus on progressive MS and just new ways of treating MS as well. I think that is not one thing. That is many, many, many things. I’m sorry, but there’s just too many things.

Dr Julia Morahan:
No, I mean it was a super exciting meeting, and I think we do have lots of really interesting and fun and exciting stuff coming through.

Fi, what about you?

Dr Fiona McKay:
Well, I’m going to be predictable and say, of course, the momentum in the EBV research, because I really think it is bringing us closer to understanding the cause of MS.

And off the back of this, I really have great hope that it’ll bring us new treatments and even ways to prevent MS in future. So, I just I think it’s such an exciting area.

Dr Julia Morahan:
Yeah, very cool.

I think for me, often going to the ACTRIMS-ECTRIMS meetings is about seeing lots of other ‘me’s’ and talking to them about the research that’s happening on the global stage and the way that Australia can contribute to those international efforts.

So, at the global research strategy meeting we had the national MS organisations from all around the world. And we spent some time discussing the promising interim results of the UK Octopus trial of neuroprotective therapies for progressive MS, which is fantastic. And our plans to continue the trial in 2027, including via the Australian arm known as PLATYPUS.

We also discussed how our organisations will come together to work on early detection and prevention of MS. And I just think that the unity and the momentum of the global MS community has already brought so many wins and gives me hope for many more to come.

(Today) we all used…overused the word ‘momentum’ in responses…because it’s true.

Okay, so Tennille and Fiona, Dr Luker and Dr McKay, thank you for joining me and for bringing the highlights of MSToronto 2026 home to our community.

Today, we’ve heard how a unified biological understanding of MS is reshaping

research, how new treatments are targeting the hidden processes behind progression, and how work on risk factors such as Epstein-Barr virus is bringing prevention closer.

We’ve also heard how Australian researchers are contributing on the world stage—guided by the priorities you, our community, have told us matter most.

There is still so much to, but the momentum is real and every step brings us closer to better treatments, preventions and a cure.

To read more about our research updates from the meeting, you can head to our WIRE newsletter article on ‘Unifying MS’, also linked in the show notes.

To learn more about the research MS Australia funds and how you get involved, visit msaustralia.org.au forward slash research.

Thank you for listening. Please share this episode with anyone who is interested in MS research and join us next time on The Raw Nerve.

Voiceover:
Thanks for listening to The Raw Nerve, the official podcast of MS Australia.

To hear more, subscribe to our podcast today at: msaustralia.org.au/podcast

Views expressed on the Raw Nerve Podcast, including any discussions or reference to medications or treatments by podcast guests, do not necessarily represent the views of MS Australia and should not be seen as either an endorsement or rejection of a treatment.

MS Australia does not recommend any specific treatment for people living with MS. Decisions about any treatments, taking into consideration the potential benefits and side effects for each individual’s circumstances, should be made in careful consultation with the person’s neurologist.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

MSToronto 2026: Unifying MS and the Future of Research